Use of a risk scoring tool to identify higher-risk HIV-1 serodiscordant couples for an antiretroviral-based HIV-1 prevention intervention

Elizabeth M Irungu, Renee Heffron, Nelly Mugo, Kenneth Ngure, Elly Katabira, Nulu Bulya, Elizabeth Bukusi, Josephine Odoyo, Stephen Asiimwe, Edna Tindimwebwa, Connie Celum, Jared M Baeten, Partners Demonstration Project Team, Jared Baeten, Connie Celum, Renee Heffron, Deborah Donnell, Ruanne Barnabas, Jessica Haberer, Harald Haugen, Craig Hendrix, Lara Kidoguchi, Mark Marzinke, Susan Morrison, Jennifer Morton, Norma Ware, Monique Wyatt, Elly Katabira, Nulu Bulya, Elizabeth Bukusi, Josephine Odoyo, Nelly Mugo, Kenneth Ngure, Elizabeth M Irungu, Renee Heffron, Nelly Mugo, Kenneth Ngure, Elly Katabira, Nulu Bulya, Elizabeth Bukusi, Josephine Odoyo, Stephen Asiimwe, Edna Tindimwebwa, Connie Celum, Jared M Baeten, Partners Demonstration Project Team, Jared Baeten, Connie Celum, Renee Heffron, Deborah Donnell, Ruanne Barnabas, Jessica Haberer, Harald Haugen, Craig Hendrix, Lara Kidoguchi, Mark Marzinke, Susan Morrison, Jennifer Morton, Norma Ware, Monique Wyatt, Elly Katabira, Nulu Bulya, Elizabeth Bukusi, Josephine Odoyo, Nelly Mugo, Kenneth Ngure

Abstract

Background: Antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) reduce HIV-1 transmission within heterosexual HIV-1 serodiscordant couples. Prioritizing couples at highest HIV-1 transmission risk for ART and PrEP would maximize impact and minimize costs.

Methods: The Partners Demonstration Project is an open-label, delivery study of integrated PrEP and ART for HIV-1 prevention among high risk HIV-1 serodiscordant couples in Kenya and Uganda. We evaluated the feasibility of using a validated risk score that weighs a combination of easily measurable factors (age, children, marital status, male circumcision status, condom use, plasma HIV-1 levels) to identify couples at highest risk for HIV-1 transmission for enrollment. Couples scoring ≥5 met the risk score eligibility criteria.

Results: We screened 1694 HIV-1 serodiscordant couples and enrolled 1013. Of the screened couples, 1331 (78.6 %) scored ≥5 (with an expected incidence >3 % per year) and 76 % of these entered the study. The median age of the HIV-1 uninfected partner was 29 years [IQR 26, 36] and 20 % were <25 years of age. The HIV-1 uninfected partner was male in 67 % of partnerships, 33 % of whom were uncircumcised, 57 % of couples had no children, and 65 % reported unprotected sex in the month prior to enrollment. Among HIV-1 infected partners, 41 % had plasma viral load >50,000 copies/ml.

Conclusion: A risk scoring tool identified HIV-1 serodiscordant couples for a demonstration project of PrEP and ART with high HIV-1 risk. The tool may be feasible for research and public health settings to maximize efficiency and minimize HIV-1 prevention costs.

Keywords: Africa; Delivery; HIV; PrEP; Screening tool; Serodiscordant couples.

Figures

Fig. 1
Fig. 1
HIV-1 risk score worksheet
Fig. 2
Fig. 2
Flow chart of HIV-1 serodiscordant couples screened for eligibility to the Partners Demonstration Project
Fig. 3
Fig. 3
Proportion of enrolled couples in each CD4 category, by risk score

References

    1. Dunkle KL, Stephenson R, Karita E, Chomba E, Kayitenkore K, Vwalika C, Greenberg L, Allen S. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet. 2008;371(9631):2183–2191. doi: 10.1016/S0140-6736(08)60953-8.
    1. De Walque D. Sero-discordant couples in five African countries: Implications for prevention strategies. Popul Dev Rev. 2007;33(3):501–523. doi: 10.1111/j.1728-4457.2007.00182.x.
    1. Gray R, Ssempiija V, Shelton J, Serwadda D, Nalugoda F, Kagaayi J, Kigozi G, Wawer MJ. The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda. Aids. 2011;25(6):863–865. doi: 10.1097/QAD.0b013e3283448790.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi: 10.1056/NEJMoa1105243.
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. doi: 10.1056/NEJMoa1108524.
    1. El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS. 2011;25(18):2295–2299. doi: 10.1097/QAD.0b013e32834c4c22.
    1. Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin I, Delany S, Garnett GP, Gray G, Johnson L, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8(11):e1001123. doi: 10.1371/journal.pmed.1001123.
    1. Curran K, Baeten JM, Coates TJ, Kurth A, Mugo NR, Celum C. HIV-1 prevention for HIV-1 serodiscordant couples. Curr HIV/AIDS Rep. 2012;9(2):160–170. doi: 10.1007/s11904-012-0114-z.
    1. Cremin I, Hallett T. Estimating the range of potential epidemiological impact of pre-exposure prophylaxis: run-away success or run-away failure? AIDS (London, England) 2015;29:733–739. doi: 10.1097/QAD.0000000000000591.
    1. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, Njuguna S, Mugo N, Bukusi E, Manongi R, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013;62(3):339–347. doi: 10.1097/QAI.0b013e31827e622d.
    1. Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART [abstract 24]. Presented at: CROI 2015. Seattle: Conference on Retroviruses and Opportunistic Infections. 2015.
    1. Ministry of Health. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: A rapid advice. Nairobi: National AIDS and STI Control Program (NASCOP); 2014.
    1. WHO. Guidance on Couples HIV Testing and Counselling Including Antiretroviral Therapy for Treatment and Prevention in Serodiscordant Couples. Geneva: World Health Organisation; 2012.
    1. Mujugira A, Celum C, Thomas KK, Farquhar C, Mugo N, Katabira E, Bukusi EA, Tumwesigye E, Baeten JM. Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2014;66(4):436–442. doi: 10.1097/QAI.0000000000000192.
    1. Mujugira A, Thomas K, Celum C, Farquhar C, Baeten JM, D D, Bukusi E. HIV-1 Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy [Abstract 989]. Presented at: CROI 2015. Seattle: Conference on Retroviruses and Opportunistic Infections; 2015.
    1. Barnabas RV, van Rooyen H, Tumwesigye E, Murnane PM, Baeten JM, Humphries H, Turyamureeba B, Joseph P, Krows M, Hughes JP, et al. Initiation of antiretroviral therapy and viral suppression after home HIV testing and counselling in KwaZulu-Natal, South Africa, and Mbarara district, Uganda: a prospective, observational intervention study. The Lancet HIV. 2014;1(2):e68–e76. doi: 10.1016/S2352-3018(14)70024-4.
    1. Genberg BL, Naanyu V, Wachira J, Hogan JW, Sang E, Nyambura M, Odawa M, Duefield C, Ndege S, Braitstein P. Linkage to and engagement in HIV care in western Kenya: An observational study using population-based estimates from home-based counseling and testing. The lancet HIV. 2015;2(1):e20–e26. doi: 10.1016/S2352-3018(14)00034-4.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren